Related Experiment Video
Updated: Jul 18, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
Published on: August 28, 2020
Effectiveness of tolterodine in nonneurogenic voiding dysfunction
1Pediatric Urology Unit, Sri Ramachandra Medical College and Research Institute, Chennai, India. kidsdocs@sancharnet.in
Insights
Long-acting tolterodine effectively treats non-neurogenic voiding dysfunction in children. This medication showed significant symptom improvement and high compliance with a once-daily dosage.
Area of Science:
- Pediatric Urology
- Pharmacology
- Clinical Medicine
Background:
- Non-neurogenic voiding dysfunction (NNVD) is a common condition in children.
- Current treatment options for NNVD may have limitations in efficacy and compliance.
Purpose of the Study:
- To evaluate the efficacy and safety of long-acting tolterodine in pediatric patients with NNVD.
- To assess the impact of tolterodine on the dysfunctional voiding symptom score (DVSS).
Main Methods:
- A study involving 44 children diagnosed with NNVD.
- Patients received either 2mg or 4mg of long-acting tolterodine tartrate once daily.
- The Dysfunctional Voiding Symptom Score (DVSS) was used to measure symptom severity before and after treatment.
Main Results:
- A significant reduction in mean DVSS was observed post-treatment (P < 0.01).
- Symptomatic cure was achieved in 63.6% of patients, with improvement in 31.8%.
- High compliance (95%) and a favorable side effect profile were noted with the once-daily dosing regimen.
Conclusions:
- Long-acting tolterodine is an effective treatment for children with non-neurogenic voiding dysfunction.
- The once-daily formulation offers good compliance and a minimal side effect profile in pediatric patients.
- Tolterodine demonstrates a significant positive impact on voiding symptoms in children.
Abstract:
The efficacy of tolterodine was analysed in children with non-neurogenic voiding dysfunction, using dysfunctional voiding symptom score (DVSS). Of 44 patients (mean age 9.3 yrs; M:F = 25:19), 36 received long acting tolterodine tartrate at a dose of 2mg OD and 8 at a dose of 4mg OD. The mean (SD) DVSS before and after the treatment was 17.1 (2.8) and 12.0 (2.4). There was a significant improvement in the mean DVSS score at the end of the treatment (Students t test P < 0.01). The dysfunctional symptoms were cured in 28(63.6 %), improved in 14(31.8 %) and failed to show improvement in 2 (4.6 %). Over all 95 % were compliant with the single daily medication. Our results demonstrate that long acting tolterodine is effective in children with voiding dysfunction. The single daily dose has good compliance and minimal side effect profile.
Related Concept Videos
Urodynamic Studies: Uroflowmetry
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Urinary Tract Calculi III: Medical Management
Urinary Tract Infection IV: Nursing Management
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
The Micturition Reflex
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating urine...
